Literature DB >> 16528475

Regulation of survivin by retinoic acid and its role in paclitaxel-mediated cytotoxicity in MCF-7 breast cancer cells.

M A Christine Pratt1, Min-Ying Niu, L Isabel Renart.   

Abstract

The chemotherapeutic drug paclitaxel induces microtubular stabilization and mitotic arrest associated with increased survivin expression. Survivin is a member of the inhibitor of apoptosis (iap) family which is highly expressed in during G2/M phase where it regulates spindle formation during mitosis. It is also constitutively overexpressed in most cancer cells where it may play a role in chemotherapeutic resistance. MCF-7 breast cancer cells stably overexpressing the sense strand of survivin (MCF-7(survivin-S) cells) were more resistant to paclitaxel than cells depleted of survivin (MCF-7(survivin-AS) despite G2/M arrest in both cell lines. However, survivin overexpression did not protect cells relative to control MCF-7(pcDNA3) cells. Paclitaxel-induced cytotoxicity can be enhanced by retinoic acid and here we show that RA strongly reduces survivin expression in MCF-7 cells and prevents paclitaxel-mediated induction of survivin expression. Mitochondrial release of cytochrome c after paclitaxel alone or in combination with RA was weak, however robust Smac release was observed. While RA/paclitaxel-treated MCF-7 (pcDNA3) cultures contained condensed apoptotic nuclei, MCF-7(survivin-S) nuclei were morphologically distinct with hypercondensed disorganized chromatin and released mitochondrial AIF-1. RA also reduced paclitaxel-associated levels of cyclin B1 expression consistent with mitotic exit. MCF-7(survivin-S) cells displayed a 30% increase in >2N/<4N ploidy while there was no change in this compartment in vector control cells following RA/paclitaxel. We propose that RA sensitizes MCF-7 cells to paclitaxel at least in part through survivin downregulation and the promotion of aberrant mitotic progression resulting in apoptosis. In addition we provide biochemical and morphological data which suggest that RA-treated MCF-7(survivin-S) cells can also undergo catastrophic mitosis when exposed to paclitaxel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16528475     DOI: 10.1007/s10495-006-4603-7

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  10 in total

1.  Survivin is not induced by novel taxanes.

Authors:  Nima Sharifi; Jun Qi; Susan Bane; Shubhada Sharma; Rui Li; Robert Robey; William D Figg; William L Farrar; David G I Kingston
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

2.  The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Authors:  Yong-Gang Lv; Fang Yu; Qing Yao; Jiang-Hao Chen; Ling Wang
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

3.  Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: survivin expression overlaps with stem cell markers.

Authors:  Fengzhi Li; Qiuying Cheng; Xiang Ling; Aimee Stablewski; Lei Tang; Barbara A Foster; Candace S Johnson; Youcef M Rustum; Carl W Porter
Journal:  Am J Pathol       Date:  2010-02-04       Impact factor: 4.307

4.  Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin.

Authors:  Xiang Ling; Xiang He; Pasha Apontes; Felicia Cao; Rami G Azrak; Fengzhi Li
Journal:  Am J Transl Res       Date:  2009-07-15       Impact factor: 4.060

5.  Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival.

Authors:  Praful R Nair; Cory Alvey; Xiaoling Jin; Jerome Irianto; Irena Ivanovska; Dennis E Discher
Journal:  Bioconjug Chem       Date:  2018-03-01       Impact factor: 4.774

6.  Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.

Authors:  Jing Lu; Ming Tan; Wen-Chien Huang; Ping Li; Hua Guo; Ling-Ming Tseng; Xiao-hua Su; Wen-Tao Yang; Warapen Treekitkarnmongkol; Michael Andreeff; Fraser Symmans; Dihua Yu
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

7.  Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy.

Authors:  Wensheng Liu; Margot M Ip; Matthew B Podgorsak; Gokul M Das
Journal:  Breast Cancer Res Treat       Date:  2008-05-15       Impact factor: 4.872

8.  Retinoic acid-treated pluripotent stem cells undergoing neurogenesis present increased aneuploidy and micronuclei formation.

Authors:  Rafaela C Sartore; Priscila B Campos; Cleber A Trujillo; Bia L Ramalho; Priscilla D Negraes; Bruna S Paulsen; Tamara Meletti; Elaine S Costa; Leonardo Chicaybam; Martin H Bonamino; Henning Ulrich; Stevens K Rehen
Journal:  PLoS One       Date:  2011-06-06       Impact factor: 3.240

9.  Retinoic acid and cancer treatment.

Authors:  Mei-Chih Chen; Shih-Lan Hsu; Ho Lin; Tsung-Ying Yang
Journal:  Biomedicine (Taipei)       Date:  2014-11-28

10.  Redox-sensitive micelles for targeted intracellular delivery and combination chemotherapy of paclitaxel and all-trans-retinoid acid.

Authors:  Lingfei Han; Lejian Hu; Fulei Liu; Xin Wang; Xiaoxian Huang; Bowen Liu; Feng Feng; Wenyuan Liu; Wei Qu
Journal:  Asian J Pharm Sci       Date:  2018-09-24       Impact factor: 6.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.